Sponsors (2)
The bill creates a centralized USDA biotechnology office to accelerate research, coordination, and adoption—benefitting farmers, researchers, and consumers through clearer guidance and faster innovation—but it raises administrative costs and risks favoring large agribusiness and reducing perceived regulatory caution unless safeguards and equitable supports are added.
Farmers and agricultural producers will get coordinated USDA guidance, extension support, and clearer communication on biotechnology, making adoption and commercialization decisions easier and lowering barriers to using biotech tools.
Scientists and biotech developers will have a central USDA office that prioritizes R&D and improves interagency coordination, which can speed innovation and commercialization of agricultural biotech.
Consumers may receive clearer labeling and better coordinated regulatory oversight of biotech products, improving information available at purchase and potentially enhancing safety oversight.
Small farms and smaller agribusinesses could be disadvantaged because emphasis on commercialization and trade may primarily benefit larger agribusinesses and biotech firms unless paired with targeted equitable supports.
Consumers and some producers may face increased risk if centralized USDA biotech leadership leads to streamlined approvals that reduce perceived regulatory caution or oversight.
Taxpayers will bear higher federal administrative costs to create and staff a new Office within USDA.
Based on analysis of 2 sections of legislative text.
Establishes an Office of Biotechnology Policy at USDA to coordinate biotechnology, synthetic biology, and biomanufacturing policy, interagency work, outreach, and commercialization support.
Introduced September 3, 2025 by Alejandro Padilla · Last progress September 3, 2025
Creates a new Office of Biotechnology Policy inside the U.S. Department of Agriculture to coordinate federal policy and activities on biotechnology, biomanufacturing, synthetic biology, and related technologies. The office will be led by a Director reporting to the Secretary and will develop policy, coordinate R&D and commercialization efforts, lead interagency work with agencies like EPA and FDA, and consult with industry, academics, producers, and other stakeholders. The law also adds explicit statutory authority for the Secretary to carry out these responsibilities. The bill focuses on organization, coordination, communication, and stakeholder consultation rather than specifying new funding or regulatory changes.